High false-negative rate of anti-HCV among Egyptian patients on regular hemodialysis

Hemodialysis International

Volumn 16, Issue 3, 2012, Pages 420-427

  El Sherif, Assem ^a   Elbahrawy, Ashraf ^a   Aboelfotoh, Atef ^a   Abdelkarim, Magdy ^a   Saied Mohammad, Abdel Gawad ^a   Abdallah, Abdallah Mahmoud ^a   Mostafa, Sadek ^a   Elmestikawy, Amr ^a   Elwassief, Ahmed ^a   Salah, Mohamed ^a   Abdelbaseer, Mohamed Ali ^b   Abdelwahab, Kouka Saadeldin ^c  

^a AL AZHAR UNIVERSITY   (Egypt)

^b AL AZHAR UNIVERSITY   (Egypt)

^c Assiut Branch   (Egypt)

Author keywords

Anti HCV; Egyptian patients; Hemodialysis; NAT

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS RNA;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; EGYPT; FALSE NEGATIVE RESULT; FEMALE; HEMODIALYSIS; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; VIRUS IDENTIFICATION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; EGYPT; FALSE NEGATIVE REACTIONS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; REAL-TIME POLYMERASE CHAIN REACTION; RENAL DIALYSIS; RNA, VIRAL; VIREMIA;

EID: 84863422223     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00662.x     Document Type: Article

References (45)

1. Arthur RR, Hassan NF, Abdallah MY, etal. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg. 1997; 91:271-274.
2. Rahnavardi M, Moghaddam S, Alavian S. Hepatitis C in hemodialysis patients: Current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol. 2008; 28:628-640.
3. Wreghitt TG. Blood-borne virus infections in dialysis units-A review. Rev Med Virol. 1999; 9:101-109.
4. Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: A multicentre study in 2796 patients. Gut. 2002; 51:429-433.
5. Savey A, Simon F, Izopet J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol. 2005; 26:752-760.
6. Delarocque-Astagneau E, Baffoy N, Thiers V, etal. Outbreak of hepatitis C virus infection in a hemodialysis unit: Potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol. 2002; 23:328-334.
7. Harmankaya O, Cetin B, Obek A, Seber E. Low prevalence of hepatitis C virus infection in hemodialysis units: Effect of isolation? Ren Fail. 2002; 24:639-644.
8. Taskapan H, Oymak O, Dogukan A, Utas C. Patient to patient transmission of hepatitis C virus in hemodialysis units. Clin Nephrol. 2001; 55:477-481.
9. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis. 2005; 46:290-300.
10. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int. 1998; 53:1022-1025.
11. Gilli P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatitis C virus in dialysis units. Nephron. 1995; 70:301-306.
12. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001; 50:1-43.
13. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998; 47:1-39.
14. Natov SN, Pereira BJ. Routine serologic testing for hepatitis C virus infection should be instituted among dialysis patients. Semin Dial. 2000; 13:393-398.
15. Fabrizi F, Bunnapradist S, Lunghi G, Aucella F, Martin P. Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Recent evidence. Minerva Urol Nefrol. 2004; 56:249-257.
16. Muerhoff AS, Jiang L, Shah DO, etal. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion. 2002; 42:349-356.
17. Fabrizi F, De Vecchi AF, Como G, Lunghi G, Martin P. De novo HCV infection among dialysis patients: A prospective study by HCV core antigen ELISA assay. Aliment Pharmacol Ther. 2005; 21:861-869.
18. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002; 122:308-313.
19. Agha S, Tanaka Y, Saudy N, etal. Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3 and 4 infected blood donors: A collaborative study between Japan, Egypt, and Uzbekistan. J Med Virol. 2004; 73:216-222.
20. Pereira B, Levey A. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997; 51:981-999.
21. Sakamoto N, Enomoto N, Marumo F, Sato C. Prevalence of hepatitis C virus infection among long-term hemodialyis patients: Detection of hepatitis C virus RNA in plasma. J Med Virol. 1993; 39:11-15.
22. Sheu JC, Lee SH, Wang JT, Shin LN, Wang TH, Chen DS. Prevalence of anti-HCV and HCV viremia in hemodialysis patients in Taiwan. J Med Virol. 1992; 37:108-112.
23. Hayashi J, Nakashima K, Yoshimura E, Kishihara Y, Ohmiya M, Hirata M. Prevalence and role of hepatitis C viraemia in haemodialysis patients in Japan. J Infect. 1994; 28:271-277.
24. Chan TM, Lok ASF, Cheng IKP, Chan RT. Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays. Hepatology. 1993; 17:5-8.
25. Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: Failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis. 1993; 168:1343-1348.
26. Kelley VA, Everett-Kitchens J, Brannon LE, etal. Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. Transplantation. 2002; 74:1473-1475.
27. Dentico P, Buongiorno R, Volpe A, etal. Prevalence and incidence of hepatitis C virus (HCV) in hemodialysis patients: Study of risk factors. Clin Nephrol. 1992; 38:49-52.
28. Mitwalli A, Al-Mohaya S, Al-Wakeel J, etal. Hepatitis C in chronic renal failure patients. Am J Nephrol. 1992; 12:288-291.
29. Weiner AJ, Brauer MJ, Rosenblatf J, etal. Variable and hypervariable domains are found in the regions of HCV corresponding to the fiavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology. 1991; 180:842-848.
30. Alter MJ, Margolis HS, Krawczynski K, etal. The natural history of community-acquired hepatitis C in the United States. The Sentinel Countries Chronic non-A, non-B Hepatitis Study Team. NEJM. 1992; 327:1899-1905.
31. Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. Transfusion. 1995; 35:903-910.
32. Barrera JM, Francis B, Ercilla G, etal. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang. 1995; 68:15-18.
33. Furusyo N, Hayashi J, Kakuda K, etal. Acute hepatitis C among Japanese hemodialysis patients: A prospective 9-year study. Am J Gastroenterol. 2001; 96:1593-1600.
34. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984; 311:496-501.
35. Descamps-Latscha B, Witko-Sarsat V, Jungers P. Infection and immunity in end stage renal disease. In: Henrich WL, ed. Principals and Practice of Dialysis 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2004; 307-322.
36. Thomson EC, Nastouli E, Main J, etal. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS. 2009; 23:89-93.
37. Fouque D, Kalantar-Zadeh K, Kopple J, etal. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008; 73:391-398.
38. Wolfson M, Strong CJ, Minturn D, Gray DK, Kopple JD. Nutritional status and lymphocyte function in maintenance hemodialysis patients. Am J Clin Nutr. 1984; 39:547-555.
39. Reddan DN, Klassen PS, Szczech LA, etal. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant. 2003; 18:1167-1173.
40. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000; 11:1896-1902.
41. Epinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti-HCV positive long-term hemodialysis patients. Nephrol Dial Transplant. 2001; 16:1669-1674.
42. Pereira BJG, Natov SN, Bouthot BA, etal. Effect of hepatitis C infection and renal transplantation in end stage renal disease. Kidney Int. 1998; 53:1374-1381.
43. Goodkin DA, Bragg-Gresham JL, Koenig KG, etal. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcome and Practice Pattern Study (DOOPS). J Am Soc Nephrol. 2003; 7:3-35.
44. Anonymous. The current state of chronic dialysis treatment in Japan (as of December 31, 2000). Ther Apher Dial. 2003; 7:3-35.
45. Stramer SL, Glynn SA, Kleinman SH, etal. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004; 351:760-768.